STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 28, 2019	$ 131,449	$ 121,705,250	$ (122,023,347)	$ (186,648)
Balance (in shares) at Feb. 28, 2019	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		138,217		138,217
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		316,719		316,719
Net loss			(468,314)	(468,314)
Balance at May. 31, 2019	$ 131,449	122,160,186	(122,491,661)	(200,026)
Balance (in shares) at May. 31, 2019	131,448,444
Balance at Feb. 28, 2019	$ 131,449	121,705,250	(122,023,347)	(186,648)
Balance (in shares) at Feb. 28, 2019	131,448,444
Increase (Decrease) in Stockholders' Equity
Net loss				(878,534)
Balance at Aug. 31, 2019	$ 131,449	122,587,968	(122,901,881)	(182,464)
Balance (in shares) at Aug. 31, 2019	131,448,444
Balance at May. 31, 2019	$ 131,449	122,160,186	(122,491,661)	(200,026)
Balance (in shares) at May. 31, 2019	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		144,067		144,067
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		283,715		283,715
Net loss			(410,220)	(410,220)
Balance at Aug. 31, 2019	$ 131,449	122,587,968	(122,901,881)	(182,464)
Balance (in shares) at Aug. 31, 2019	131,448,444
Balance at Feb. 29, 2020	$ 131,449	123,373,793	(123,657,829)	(152,587)
Balance (in shares) at Feb. 29, 2020	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		83,317		83,317
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		281,978		281,978
Net loss			(457,970)	(457,970)
Balance at May. 31, 2020	$ 131,449	123,739,088	(124,115,799)	(245,262)
Balance (in shares) at May. 31, 2020	131,448,444
Balance at Feb. 29, 2020	$ 131,449	123,373,793	(123,657,829)	(152,587)
Balance (in shares) at Feb. 29, 2020	131,448,444
Increase (Decrease) in Stockholders' Equity
Net loss				(786,510)
Balance at Aug. 31, 2020	$ 131,449	124,111,504	(124,444,339)	(201,386)
Balance (in shares) at Aug. 31, 2020	131,448,444
Balance at May. 31, 2020	$ 131,449	123,739,088	(124,115,799)	(245,262)
Balance (in shares) at May. 31, 2020	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		139,017		139,017
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		233,399		233,399
Net loss			(328,540)	(328,540)
Balance at Aug. 31, 2020	$ 131,449	$ 124,111,504	$ (124,444,339)	$ (201,386)
Balance (in shares) at Aug. 31, 2020	131,448,444